• "Where Do We Go From Here?" Targeted Therapies Lead to Challenging Choices in Breast Cancer

  • Sep 27 2024
  • Duración: 11 m
  • Podcast

"Where Do We Go From Here?" Targeted Therapies Lead to Challenging Choices in Breast Cancer

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Newly approved targeted therapies for patients with advanced hormone
    receptor (HR)-positive, HER2-negative breast cancer are changing care. “We
    have an abundance of opportunities, but challenges with having to choose
    the right opportunity at the right time,” says Robert A. Figlin, MD, the Steven
    Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer
    Center in Los Angeles. Dr. Figlin discusses how to navigate new options with
    Manali Bhave, MD, a breast medical oncologist and assistant professor at the
    Emory University School of Medicine in Atlanta. Dr. Bhave stresses that
    disease progression in breast cancer can’t be addressed with a one-size-fits-
    all option. “Where do we go from here? I think it is largely dependent on
    clinical factors, patient comorbidities, and even biomarker status,” she
    explains. Dr. Bhave and Dr. Figlin discuss recent developments in targeted
    therapies and important challenges. “We’ve come a long way in treating
    metastatic HR-positive, HER2-negative breast cancer as more of a chronic
    disease,” she says.


    Dr. Bhave reported consulting fees from Lilly, Novartis, and AstraZeneca.


    Dr. Figlin reported various financial relationships.
    Más Menos
Más Menos
activate_Holiday_promo_in_buybox_DT_T2

Lo que los oyentes dicen sobre "Where Do We Go From Here?" Targeted Therapies Lead to Challenging Choices in Breast Cancer

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles